Pyruvate kinase M2 regulates kidney fibrosis through pericyte glycolysis during the progression from acute kidney injury to chronic kidney disease

Abstract

We aimed to investigate the role of renal pericyte pyruvate kinase M2 (PKM2) in the progression of acute kidney injury (AKI) to chronic kidney disease (CKD). The role of PKM2 in renal pericyte-myofibroblast transdifferentiation was investigated in an AKI-CKD mouse model. Platelet growth factor receptor beta (PDGFRβ)-iCreERT2; tdTomato mice were used for renal pericyte tracing. Western blotting and immunofluorescence staining were used to examine protein expression. An 5-ethynyl-2′-deoxyuridine assay was used to measure renal pericyte proliferation. A scratch cell migration assay was used to analyse cell migration. Seahorse experiments were used to examine glycolytic rates. Enzyme-linked immunoassay was used to measure pyruvate kinase enzymatic activity and lactate concentrations. The PKM2 nuclear translocation inhibitors Shikonin and TEPP-46 were used to alter pericyte transdifferentiation. In AKI-CKD, renal pericytes proliferated and transdifferentiated into myofibroblasts and PKM2 is highly expressed in renal pericytes. Shikonin and TEPP-46 inhibited pericyte proliferation, migration, and pericyte-myofibroblast transdifferentiation by reducing nuclear PKM2 entry. In the nucleus, PKM2 promoted downstream lactate dehydrogenase A (LDHA) and glucose transporter 1 (GLUT1) transcription, which are critical for glycolysis. Therefore, PKM2 regulates pericyte glycolytic and lactate production, which regulates renal pericyte-myofibroblast transdifferentiation. PKM2-regulated renal pericyte-myofibroblast transdifferentiation by regulating downstream LDHA and GLUT1 transcription and lactate production. Reducing nuclear PKM2 import can reduce renal pericytes-myofibroblasts transdifferentiation, providing new ideas for AKI-CKD treatment.

References

[1] Zuk A, Bonventre JV. Acute kidney injury. Annu Rev Med. 2016;67:293-307.

[2] See EJ, Jayasinghe K, Glassford N, et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int. 2019;95(1):160-172.

[3] Ortiz A. PDGFR-beta and kidney fibrosis. EMBO Mol Med. 2020;12(3):e11729.

[4] Kuppe C, Ibrahim MM, Kranz J, et al. Decoding myofibroblast origins in human kidney fibrosis. Nature. 2021;589(7841):281-286.

[5] Ren S, Duffield JS. Pericytes in kidney fibrosis. Curr Opin Nephrol Hypertens. 2013;22(4):471-480.

[6] Yang W, Lu Z. Pyruvate kinase M2 at a glance. J Cell Sci. 2015;128(9):1655-1660.

[7] Amin S, Yang P, Li Z. Pyruvate kinase M2: a multifarious enzyme in non-canonical localization to promote cancer progression. Biochim Biophys Acta Rev Cancer. 2019;1871(2):331-341.

[8] Lan R, Geng H, Singha PK, et al. Mitochondrial pathology and glycolytic shift during proximal tubule atrophy after ischemic AKI. J Am Soc Nephrol. 2016;27(11):3356-3367.

[9] Cheon JH, Kim SY, Son JY, et al. Pyruvate kinase M2: a novel biomarker for the early detection of acute kidney injury. Toxicol Res. 2016;32(1):47-56.

[10] Wang TT, Wu LL, Wu J, et al. 14-3-3zeta inhibits maladaptive repair in renal tubules by regulating YAP and reduces renal interstitial fibrosis. Acta Pharmacol Sin. 2023;44(2):381-392.

[11] Zhou L, Li Y, Zhou D, Tan RJ, Liu Y. Loss of klotho contributes to kidney injury by derepression of Wnt/β-catenin signaling. J Am Soc Nephrol. 2013;24(5):771-785.

[12] Ritsma L, Steller EJ, Ellenbroek SI, et al. Surgical implantation of an abdominal imaging window for intravital microscopy. Nat Protoc. 2013;8(3):583-594.

[13] Lim JH, Yook JM, Oh SH, et al. Paricalcitol improves hypoxia-induced and TGF-β1-induced injury in kidney Pericytes. Int J Mol Sci. 2021;22(18):9751.

[14] Xu C, Hong Q, Zhuang K, et al. Regulation of pericyte metabolic reprogramming restricts the AKI to CKD transition. Metabolism. 2023;145:155592.

[15] Chou YH, Pan SY, Shao YH, et al. Methylation in pericytes after acute injury promotes chronic kidney disease. J Clin Invest. 2020;130(9):4845-4857.

[16] Lee YB, Min JK, Kim JG, et al. Multiple functions of pyruvate kinase M2 in various cell types. J Cell Physiol. 2021;237(1):128-148.

[17] Wang HJ, Hsieh YJ, Cheng WC, et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α-mediated glucose metabolism. Proc Natl Acad Sci U S A. 2014;111(1):279-284.

[18] Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F. PKM2, function and expression and regulation. Cell Biosci. 2019;9:52.

[19] Luo W, Hu H, Chang R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011;145(5):732-744.

[20] Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK. Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol. 2015;26(8):1765-1776.

[21] Schiessl IM, Grill A, Fremter K, Steppan D, Hellmuth MK, Castrop H. Renal interstitial platelet-derived growth factor receptor-beta cells support proximal tubular regeneration. J Am Soc Nephrol. 2018;29(5):1383-1396.

[22] Chang FC, Chou YH, Chen YT, Lin SL. Novel insights into pericyte-myofibroblast transition and therapeutic targets in renal fibrosis. J Formos Med Assoc. 2012;111(11):589-598.

[23] Ding H, Jiang L, Xu J, et al. Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis. Am J Physiol Renal Physiol. 2017;313(3):F561-F575.

[24] Wei Q, Su J, Dong G, Zhang M, Huo Y, Dong Z. Glycolysis inhibitors suppress renal interstitial fibrosis via divergent effects on fibroblasts and tubular cells. Am J Physiol Renal Physiol. 2019;316(6):F1162-F1172.

[25] Yuan Q, Miao J, Yang Q, et al. Role of pyruvate kinase M2-mediated metabolic reprogramming during podocyte differentiation. Cell Death Dis. 2020;11(5):355.

[26] Zheng D, Jiang Y, Qu C, et al. Pyruvate kinase M2 Tetramerization protects against hepatic stellate cell activation and liver fibrosis. Am J Pathol. 2020;190(11):2267-2281.

[27] Gao S, Li X, Jiang Q, et al. PKM2 promotes pulmonary fibrosis by stabilizing TGF-β1 receptor I and enhancing TGF-β1 signaling. Sci Adv. 2022;8(38):eabo0987.

[28] Ye Y, Xu L, Ding H, et al. Pyruvate kinase M2 mediates fibroblast proliferation to promote tubular epithelial cell survival in acute kidney injury. FASEB J. 2021;35(7):e21706.

[29] Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol. 2011;7(4):189-200.

[30] Fu Y, Tang C, Cai J, Chen G, Zhang D, Dong Z. Rodent models of AKI-CKD transition. Am J Physiol Renal Physiol. 2018;315(4):F1098-F1106.

[31] Polichnowski AJ, Griffin KA, Licea-Vargas H, et al. Pathophysiology of unilateral ischemia-reperfusion injury: importance of renal counterbalance and implications for the AKI-CKD transition. Am J Physiol Renal Physiol. 2020;318(5):F1086-F1099.

[32] Zhang J, Wang X, Wei J, et al. A two-stage bilateral ischemia-reperfusion injury-induced AKI to CKD transition model in mice. Am J Physiol Renal Physiol. 2020;319(2):F304-F311.

[33] Shaw I, Rider S, Mullins J, Hughes J, Péault B. Pericytes in the renal vasculature: roles in health and disease. Nat Rev Nephrol. 2018;14(8):521-534.

[34] Shaw IW, O'Sullivan ED, Pisco AO, et al. Aging modulates the effects of ischemic injury upon mesenchymal cells within the renal interstitium and microvasculature. Stem Cells Transl Med. 2021;10(8):1232-1248.

[35] Kramann R, Wongboonsin J, Chang-Panesso M, Machado FG, Humphreys BD. Gli1(+) Pericyte loss induces capillary rarefaction and proximal tubular injury. J Am Soc Nephrol. 2017;28(3):776-784.

[36] Broeker KAE, Fuchs MAA, Schrankl J, et al. Different subpopulations of kidney interstitial cells produce erythropoietin and factors supporting tissue oxygenation in response to hypoxia in vivo. Kidney Int. 2020;98(4):918-931.

[37] Pozdzik AA, Giordano L, Li G, et al. Blocking TGF-beta signaling pathway preserves mitochondrial proteostasis and reduces early activation of PDGFRbeta+ pericytes in aristolochic acid induced acute kidney injury in Wistar male rats. PloS One. 2016;11(7):e0157288.

[38] Stasi A, Franzin R, Divella C, Gesualdo L, Stallone G, Castellano G. Double labeling of PDGFR-beta and alpha-SMA in swine models of acute kidney injury to detect Pericyte-to-Myofibroblast Transdifferentation as early marker of fibrosis. Bio Protoc. 2020;10(19):e3779.

[39] Wang N, Deng Y, Liu A, et al. Novel mechanism of the Pericyte-Myofibroblast transition in renal interstitial fibrosis: core fucosylation regulation. Sci Rep. 2017;7(1):16914.

[40] Li D, Zhang J, Yuan S, et al. TGF-beta1 peptide-based inhibitor P144 ameliorates renal fibrosis after ischemia-reperfusion injury by modulating alternatively activated macrophages. Cell Prolif. 2022;55(10):e13299.

[41] Alquraishi M, Puckett DL, Alani DS, et al. Pyruvate kinase M2: a simple molecule with complex functions. Free Radic Biol Med. 2019;143:176-192.

[42] Blum JE, Gheller BJ, Benvie A, et al. Pyruvate kinase M2 supports muscle progenitor cell proliferation but is dispensable for skeletal muscle regeneration after injury. J Nutr. 2021;151(11):3313-3328.

[43] Zhang A, Yu F, Yu W, et al. Pyruvate kinase M2 activation protects against the proliferation and migration of pulmonary artery smooth muscle cells. Cell Tissue Res. 2020;382(3):585-598.

[44] Zhang Q, Liu Q, Zheng S, et al. Shikonin inhibits tumor growth of ESCC by suppressing PKM2 mediated aerobic glycolysis and STAT3 phosphorylation. J Cancer. 2021;12(16):4830-4840.

[45] Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314.

[46] Warburg O, Wind F, Negelein E. The metabolism of tumors IN the body. J Gen Physiol. 1927;8(6):519-530.

[47] Nwadozi E, Rudnicki M, Haas TL. Metabolic coordination of Pericyte phenotypes: therapeutic implications. Front Cell Dev Biol. 2020;8:77.

[48] Shen Y, Jiang L, Wen P, et al. Tubule-derived lactate is required for fibroblast activation in acute kidney injury. Am J Physiol Renal Physiol. 2020;318(3):F689-F701.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.